<DOC>
	<DOC>NCT02268214</DOC>
	<brief_summary>The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes.</brief_summary>
	<brief_title>Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes</brief_title>
	<detailed_description>Study Classification: Safety, Efficacy and Pharmacokinetics/dynamics</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<criteria>Diagnosis of Type 1 Diabetes mellitus (T1DM) Central laboratory Cpeptide &lt; 0.7 ng/ml (0.23 nmol/L) Insulin use for at least 12 months per patient reported or medical records Method of insulin administration (MDI or CSII) must have been unchanged for at least 3 months prior to screening Subjects must be on a total insulin dose of ≥ 0.3 U/kg/day for at least 3 months prior to screening If on MDI insulin administration, subject must be on ≥ 3x injections per day Screening Visit: Central laboratory HbA1c ≥ 7.7% and ≤ 11.0% Body mass index (BMI) ≥ 18.5 kg/m2 History of Type 2 Diabetes mellitus (T2DM) or maturity onset diabetes of the young (MODY), pancreatic surgery, or chronic pancreatitis that could result in decreased beta cell capacity Taking metformin and/or thiazolidinediones within 2 months prior to screening Taking any antidiabetic medication (other than insulin), within 1 month prior to screening Taking GLP1 receptor agonist within 2 months prior to screening for once weekly administration and within 1 month prior to screening for once or twice daily administration History of diabetes ketoacidosis requiring medical intervention within 1 month prior to screening History of hospital admission for glycemic control (either hyperglycemia or hypoglycemia) within 1 month prior to screening Frequent episodes of severe hypoglycemia (more than one episode requiring medical assistance, emergency care), and/or glucagon therapy administered by a thirdparty individual within 1 month prior to screening History of Addison's disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Dapagliflozin</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>Add on to insulin</keyword>
	<keyword>Oral Antidiabetic</keyword>
	<keyword>Type 1 diabetes</keyword>
</DOC>